Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Giselle L. Sholler"'
Autor:
Giselle L. Sholler, Sylvain Baruchel, Meredith S. Irwin, Yvan Samson, Bing Wu, Janet Gammon, Daniel A. Morgenstern, Rosanna Yankanah, Ute Bartels, Monia Marzouki
Publikováno v:
Pediatric Blood & Cancer. 61:128-133
Background The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms. This phase I study aimed to explore the safet
Autor:
Heather McClung, Mark R. Burns, Ann M. Kendzicky, Giselle L. Sholler, Ping Zhao, André S. Bachmann, Katherine Samal, Eugene W. Gerner, Lisette P. Yco
Publikováno v:
International Journal of Cancer. 133:1323-1333
Neuroblastoma (NB) is associated with MYCN oncogene amplification occurring in approximately 30% of NBs and is associated with poor prognosis. MYCN is linked to a number of genes including ornithine decarboxylase (ODC), the rate-limiting enzyme in po
Autor:
Erika Currier, Giselle L. Sholler, Deanna Mitchell, Jacqueline M. Kraveka, Genevieve Bergendahl, Craig P. Webb, Marni A Slavik, Joel Kaplan, Gina Hanna, William Roberts, Nehal Parikh, David Cherba, Shannon R. Lenox, Emily Eugster, Suman Malempati, Jeremy A. Miller, Jeffrey P. Bond, Don Eslin, William S. Ferguson
Publikováno v:
Journal of Cancer Therapy. :602-612
Background: Neuroblastoma is the most common extracranial solid tumor in children, and treatment options for recurrent neuroblastoma are limited. Using molecular profiling to target the molecular vulnerabilities of neuroblastoma with existing therape
Autor:
Don Eslin, Erika Currier, Moeez Khan, Riyaz Basha, Pius Maliakal, Umesh T. Sankpal, Chris M. Lee, Robert M. Sutphin, Giselle L. Sholler
Publikováno v:
Molecular Carcinogenesis. 52:377-386
Current therapeutic options for recurrent neuroblastoma have poor outcomes that warrant the development of novel therapeutic strategies. Specificity protein (Sp) transcription factors regulate several genes involved in cell proliferation, survival, a
Publikováno v:
Cancer Research. 77:1934-1934
Background: A key component of high risk neuroblastoma (NB) therapy involves cis-retinoic acid (RA) for differentiation of minimal residual disease. DFMO induces differentiation and inhibition of tumor formation through the targeting of cancer stem c
Autor:
Giselle L. Sholler, Elizabeth VanSickle, Jeffrey P. Bond, Richard R. Neubig, Thomas S. Dexhemier
Publikováno v:
Cancer Research. 76:68-68
Background: High risk neuroblastoma patients have a poor response to initial chemotherapy, with 20% unable to achieve a complete response. Genomic studies have identified 6 targeted agents whose pathways have been identified in some high risk neurobl
Neuroblastoma: Ornithine Decarboxylase and Polyamines are Novel Targets for Therapeutic Intervention
Publikováno v:
Pediatric Cancer ISBN: 9789400724174
Neuroblastoma (NB) is a highly malignant solid tumor in children that is responsible for more than 15% of all paediatric cancer-related deaths. Currently there is no effective cure for high-risk NB, and the survival rate of relapsed/refractory patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b18be8fbf8b04ac74fb58c036a4fd68
https://doi.org/10.1007/978-94-007-2418-1_9
https://doi.org/10.1007/978-94-007-2418-1_9
Autor:
Giselle L. Sholler, Amy Smith, Robert M. Sutphin, Riyaz Basha, Chris M. Lee, Shanshan Wang, Umesh T. Sankpal, Ping Zhao, Don Eslin, Dennis A. Steindler, Sarah F. Connelly
Publikováno v:
Cancer Research. 74:B11-B11
Radiation (XRT) is a part of standard therapy for treating medulloblastoma (MB) in children. Morbidities associated with irradiation often cause long-term side-effects. Here we are testing a strategy to enhance the response of radiation using pre-cli
Autor:
Heather McClung, Ann M. Kendzicky, Giselle L. Sholler, Eugene W. Gerner, Katherine Samal, André S. Bachmann, Lisette P. Yco, Ping Zhao
Publikováno v:
Cancer Research. 73:2765-2765
Background: Neuroblastoma (NB) is associated with MYCN oncogene amplification occurring in approximately 30% of NBs and is associated with poor prognosis. MYCN is linked to a number of genes including ornithine decarboxylase (ODC), the rate-limiting
Autor:
Jacqueline M. Kraveka, William S. Ferguson, Bonnie LaFleur, Eugene W. Gerner, Takamaru Ashikaga, William Roberts, André S. Bachmann, Don Eslin, Deanna Mitchell, Giselle L. Sholler, Nehal Parikh, Randal K. Wada, Leonard S. Sender, Joel Kaplan, Kathleen A. Neville, Genevieve Bergendahl, Timothy Higgins, Alyssa VanderWerff
Publikováno v:
Cancer Research. 73:LB-179
Background: Neuroblastoma (NB) is the most common extracranial solid tumor in children. There is no curative treatment for children with relapsed NB, and the 5-year survival rate is Citation Format: Giselle L. Sholler, Eugene W. Gerner, Genevieve Ber